---
title: "Bavarian Nordic A/S (BVNRY.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/BVNRY.US.md"
symbol: "BVNRY.US"
name: "Bavarian Nordic A/S"
industry: "生物技术"
---

# Bavarian Nordic A/S (BVNRY.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.bavarian-nordic.com](https://www.bavarian-nordic.com) |

## Company Profile

巴伐利亚北欧 A/S 公司专注于癌症免疫疗法和传染病疫苗的开发、制造和商业化。它专门从事癌症免疫治疗，其中包括癌症管道，重点是乳腺癌、肺癌、卵巢癌和前列腺癌的治疗性疫苗。其产品包括针对埃博拉病毒、HPV、乙肝病毒和艾滋病毒疾病的 Imvamune。该公司成立于 1994 年，总部设在丹麦克维斯特加德。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:13.000Z

**Overall: B (0.27)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 33 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.94% |  |
| Net Profit YoY | 123.36% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.37 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 770.43M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.03B |  |


**Multi Score**: B

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 20.51% | A |
| Profit Margin | 35.50% | A |
| Gross Margin | 49.76% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.94% | B |
| Net Profit YoY | 123.36% | A |
| Total Assets YoY | 14.05% | B |
| Net Assets YoY | 29.24% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 281.67% | C |
| OCF YoY | 15.94% | B |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.47 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 13.20% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Bavarian Nordic A/S",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "20.51%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "35.50%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "49.76%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.94%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "123.36%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "14.05%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "29.24%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "281.67%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "15.94%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "13.20%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯维 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 2.10 | 5/605 | 4.50 | 3.85 | 2.17 |
| PB | 0.37 | 25/605 | 0.50 | 0.39 | 0.37 |
| PS (TTM) | 0.75 | 14/605 | 0.99 | 0.76 | 0.73 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/BVNRY.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/BVNRY.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/BVNRY.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.